Treace Medical Concepts Files 8-K

TL;DR

TREACE MEDICAL CONCEPTS filed an 8-K. Standard disclosure stuff.

AI Summary

On October 14, 2024, Treace Medical Concepts, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the submission of Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself were detailed in the provided text.

Why It Matters

This filing indicates Treace Medical Concepts is providing updated information or disclosures to the SEC, which could be relevant for investors monitoring the company's regulatory compliance and financial reporting.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not contain information indicating significant new risks or events.

Key Players & Entities

• TREACE MEDICAL CONCEPTS, INC. (company) — Registrant
• October 14, 2024 (date) — Earliest event reported date
• 100 Palmetto Park Place Ponte Vedra , Florida 32081 (address) — Principal executive offices
• ( 904 ) 373-5940 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share TMCI The Nasdaq

Filing Documents

• tmci-20241014.htm (8-K) — 61KB
• tmci-ex99_1.htm (EX-99.1) — 17KB
• img32504678_0.jpg (GRAPHIC) — 5KB
• 0000950170-24-114699.txt ( ) — 203KB
• tmci-20241014.xsd (EX-101.SCH) — 26KB
• tmci-20241014_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 14, 2024, Treace Medical Concepts, Inc. (the "Company") issued a press release announcing that it had filed a lawsuit against Stryker Corporation and its subsidiary Wright Medical Technology, Inc. alleging patent infringement and unfair competition. The Company also reaffirmed its previously-stated guidance on adjusted EBITDA for 2024 and expectation to reach Adjusted EBITDA breakeven in 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1 and any documents linked in that Exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Forward-Looking Statements

Forward-Looking Statements This Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company's guidance on Adjusted EBITDA for 2024 and its expectation of breakeven Adjusted EBITDA in 2025. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this Form 8-K can be found in the Risk Factors section of the Company's public filings with the Securities and Exchange Commission ("SEC"), including its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 27, 2024, and its subsequent SEC filings. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

01

Item 9.01

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release of Treace Medical Concepts, Inc. issued on October 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TREACE MEDICAL CONCEPTS, INC. Date: October 15, 2024 By: /s/ Mark L. Hair Mark L. Hair Chief Financial Officer